Clinical Trials
2 trialsNCT01243762 2018-08-16
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT00122343 2015-02-19
AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 2 Completed